Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global epidemiology of head and neck cancers: a continuing challenge.Oncology. 2016; 91: 13-23
- Management of T1-T2 glottic carcinomas.Cancer. 2004; 100: 1786-1792
- Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment?.Int J Radiat Oncol Biol Phys. 2003; 55: 322-328
- Radiation therapy for early-stage carcinoma of the oropharynx.Int J Radiat Oncol Biol Phys. 2004; 59: 743-751
- Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer.Cancer. 2016; 122: 1702-1707
- Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation.Radiother Oncol. 2012; 103: 49-56
- A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.Int J Radiat Oncol Biol Phys. 2000; 48: 7-16
- Hyperfractionated or accelerated radiotherapy for head and neck cancer.Cochrane Database Syst Rev. 2010; (CD002026)
- Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis.Lancet Oncol. 2017; 18: 1221-1237
- Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer.Lancet. 2000; 355: 949-955
- An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer.Br J Cancer. 1995; 71: 83-91
- Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials.J Clin Oncol. 1996; 14: 838-847
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.Radiother Oncol. 2009; 92: 4-14
- Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.N Engl J Med. 1991; 324: 1685-1690
- Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891.Ann Oncol. 2012; 23: 2708-2714
- Overview of platinum chemotherapy in head and neck cancer.Semin Oncol. 1994; 21: 20-27
- Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.J Clin Oncol. 1998; 16: 1310-1317
- Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.N Engl J Med. 2003; 349: 2091-2098
- Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.J Clin Oncol. 2013; 31: 845-852
- Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11.Arch Otolaryngol Head Neck Surg. 2003; 129: 44-49
- Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.N Engl J Med. 1998; 338: 1798-1804
- Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck.J Clin Oncol. 2004; 22: 3540-3548
- Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.J Clin Oncol. 2004; 22: 4665-4673
- Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.J Clin Oncol. 2005; 23: 1125-1135
- Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.Lancet Oncol. 2012; 13: 145-153
- Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.J Clin Oncol. 2005; 23: 3008-3015
- Human papillomavirus and survival of patients with oropharyngeal cancer.N Engl J Med. 2010; 363: 24-35
- Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.J Clin Oncol. 2014; 32: 3858-3866
- Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions.Ann Oncol. 2018; 29: 1130-1140
- Revisiting induction chemotherapy for head and neck cancer.Oncology (Williston Park). 2005; 19: 759-770
- Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.N Engl J Med. 2007; 357: 1695-1704
- Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.N Engl J Med. 2007; 357: 1705-1715
- Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.J Clin Oncol. 2014; 32: 2735-2743
- Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.Lancet Oncol. 2013; 14: 257-264
- A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.Ann Oncol. 2014; 25: 216-225
- Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, +/- docetaxel for larynx preservation.J Natl Cancer Inst. 2016; 108
- Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.J Clin Oncol. 2013; 31: 853-859
- Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?.Cancer. 2004; 100: 1171-1178
- E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with hpv-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group.J Clin Oncol. 2017; 35: 490-497
- Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.Int J Radiat Oncol Biol Phys. 2015; 93: 976-985
- Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.Ann Oncol. 2016; 27: 908-913
- Management of cervical lymph node metastases in squamous cell carcinoma of the tonsillar fossa, base of tongue, supraglottic larynx, and hypopharynx.Am J Surg. 1972; 124: 462-467
- Incompletely resected advanced squamous cell carcinoma of the head and neck: the effectiveness of adjuvant vs. salvage radiotherapy.Radiother Oncol. 1992; 24: 87-93
- Postoperative radiation therapy for squamous cell carcinomas of the oral cavity and oropharynx: impact of therapy on patients with positive surgical margins.Int J Radiat Oncol Biol Phys. 1993; 25: 17-21
- An analysis of factors influencing the outcome of postoperative irradiation for squamous cell carcinoma of the oral cavity.Int J Radiat Oncol Biol Phys. 1997; 39: 137-148
- Selective neck dissection for the treatment of neck metastasis from squamous cell carcinoma of the head and neck.Laryngoscope. 2002; 112: 434-438
- Expanded application of selective neck dissection with regard to nodal status.Head Neck. 1997; 19: 260-265
- Postoperative radiotherapy in head and neck carcinoma with extracapsular lymph node extension and/or positive resection margins: a comparative study.Int J Radiat Oncol Biol Phys. 1992; 23: 737-742
- Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: a matched-pair analysis.Int J Radiat Oncol Biol Phys. 1998; 40: 529-534
- Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy?.Head Neck. 1998; 20: 588-594
- Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.N Engl J Med. 2004; 350: 1945-1952
- Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.N Engl J Med. 2004; 350: 1937-1944
- Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).Head Neck. 2005; 27: 843-850
- High metastatic node number, not extracapsular spread or N-classification is a node-related prognosticator in transorally-resected, neck-dissected p16-positive oropharynx cancer.Oral Oncol. 2015; 51: 514-520
- Chemoprevention in head and neck cancer.Cancer Treat Res. 2001; 106: 221-235
- Secondary chemoprevention of upper aerodigestive tract tumors.Semin Oncol. 2001; 28: 106-120
- Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means?.Laryngoscope. 2000; 110: 1-18
- The reirradiation of recurrences of head and neck cancer.Br J Radiol. 1980; 53: 462-465
- Reirradiation of head and neck cancers. Presentation of 35 cases treated at the Gustave Roussy Institute.Radiother Oncol. 1985; 3: 27-33
- Reirradiation of recurrent head and neck cancers.Laryngoscope. 1987; 97: 85-88
- High-dose reirradiation of head and neck cancer with curative intent.Int J Radiat Oncol Biol Phys. 1994; 29: 687-698
- Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients.J Clin Oncol. 1998; 16: 3556-3562
- Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma.Cancer. 2001; 91: 2071-2076
- Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer.Head Neck. 2003; 25: 118-122
- Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.Int J Radiat Oncol Biol Phys. 2005; 61: 1096-1106
- Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.Head Neck. 2005; 27: 406-414
- RTOG 96-10: reirradiation with concurrent hydroxyurea and 5- fluorouracil in patients with squamous cell cancer of the head and neck.Int J Radiat Oncol Biol Phys. 2001; 51: 1299-1304
- Phase II trial of concurrent split course hyperfractionated radiotherapy, cisplatin, and paclitaxel in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck: results of RTOG 99-11.Proc Am Soc Clin Oncol. 2004; 23: 488
- Stereotactic body radiotherapy for recurrent head and neck cancer: a critical review.Head Neck. 2017; 39: 595-601
- The role of stereotactic body radiotherapy in reirradiation of head and neck cancer recurrence.Crit Rev Oncol Hematol. 2018; 122: 194-201
- Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.J Natl Cancer Inst. 1998; 90: 824-832
- Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.J Clin Oncol. 2000; 18: 904-914
- Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.J Clin Oncol. 2003; 21: 1980-1987
- Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.J Clin Oncol. 2004; 22: 77-85
- Developing inhibitors of the epidermal growth factor receptor for cancer treatment.J Natl Cancer Inst. 2003; 95: 851-867
- Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.J Clin Oncol. 2003; 21: 2787-2799
- Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.J Clin Oncol. 2005; 23: 5578-5587
- Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.J Clin Oncol. 2005; 23: 5568-5577
- Platinum-based chemotherapy plus cetuximab in head and neck cancer.N Engl J Med. 2008; 359: 1116-1127
- Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.J Clin Oncol. 2010; 28: 8-14
- Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck.J Clin Oncol. 2009; 27: 4448-4453
- Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.N Engl J Med. 2006; 354: 567-578
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.Lancet Oncol. 2010; 11: 21-28
- Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.Lancet Oncol. 2015; 16: 221-232
- Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 phase III randomized trial.J Clin Oncol. 2018; 36: 3077-3083
- Improved outcome by adding concurrent chemotherapy to cetuximab and radiotherapy for locally advanced head and neck carcinomas: results of the GORTEC 2007-01 phase III randomized trial.J Clin Oncol. 2018; 36: 3084-3090
- Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern Cooperative Oncology Group Trial E3303.Clin Cancer Res. 2014; 20: 5041-5051
- Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.J Clin Oncol. 2013; 31: 1415-1421
- Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.J Clin Oncol. 2014; 32: 2940-2950
- Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.Lancet Oncol. 2015; 16: 208-220
- The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck.Ann Oncol. 2014; 25: 2101-2115
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.Lancet. 2019; 393: 40-50
- Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.Lancet. 2019; 393: 51-60
- Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression.Cancer Cell. 2004; 5: 489-500
- An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas.Nat Genet. 2005; 37: 182-186
- Therapeutic insights from genomic studies of head and neck squamous cell carcinomas.Cancer Discov. 2015; 5: 239-244
- Genetic landscape of human papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors.J Clin Oncol. 2015; 33: 3227-3234
- Immunity in head and neck cancer.Cancer Immunol Res. 2015; 3: 12-17
- Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.Cancer Res. 2013; 73: 1733-1741
- B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.Cancer Res. 2003; 63: 6501-6505
- Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients.Br J Cancer. 2013; 109: 2629-2635
- PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.Cancer Res. 2013; 73: 128-138
- Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort.J Clin Oncol. 2016; 34: 3838-3845
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.Lancet Oncol. 2016; 17: 956-965
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.Lancet. 2019; 393: 156-167
- Nivolumab for recurrent squamous-cell carcinoma of the head and neck.N Engl J Med. 2016; 375: 1856-1867
Article info
Publication history
Published online: October 15, 2019
Footnotes
Disclosure: D.L. Schwartz has received royalties from UptoDate and research funding from Elekta (Sweden). D.N. Hayes is on the Merck advisory board and is a founder, stockholder, and consultant for GeneCentric.
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
